Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Buy" from Analysts

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $18.57.

ORIC has been the topic of a number of recent research reports. LADENBURG THALM/SH SH started coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a "buy" rating and a $15.00 price target on the stock. Oppenheimer cut their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush reiterated an "outperform" rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Finally, HC Wainwright restated a "buy" rating and set a $21.00 price objective on shares of Oric Pharmaceuticals in a research report on Monday, May 5th.

Oric Pharmaceuticals Stock Up 1.5%

Shares of Oric Pharmaceuticals stock traded up $0.15 during trading on Thursday, reaching $10.12. The company's stock had a trading volume of 942,341 shares, compared to its average volume of 1,164,141. The business has a 50 day moving average price of $9.94 and a 200-day moving average price of $8.15. Oric Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.67. The company has a market capitalization of $862.43 million, a P/E ratio of -5.41 and a beta of 1.69.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. Research analysts predict that Oric Pharmaceuticals will post -2.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Angie You bought 26,597 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the purchase, the director directly owned 26,597 shares in the company, valued at $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dominic Piscitelli sold 32,466 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00. Following the completion of the sale, the chief financial officer owned 68,317 shares of the company's stock, valued at approximately $717,328.50. The trade was a 32.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $416,289 in the last ninety days. Insiders own 6.82% of the company's stock.

Institutional Trading of Oric Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its position in Oric Pharmaceuticals by 17,300.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock valued at $25,000 after acquiring an additional 2,422 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Oric Pharmaceuticals in the fourth quarter valued at approximately $50,000. Arizona State Retirement System bought a new position in Oric Pharmaceuticals in the 1st quarter worth approximately $56,000. BNP Paribas Financial Markets bought a new position in Oric Pharmaceuticals in the 4th quarter worth approximately $71,000. Finally, Hsbc Holdings PLC acquired a new position in Oric Pharmaceuticals during the 1st quarter worth $102,000. Institutional investors and hedge funds own 95.05% of the company's stock.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.